

Preparation of FMD bivalent vaccine A&O by estimation of 146s antigen in the cattle dose and its evaluation by using serological technique and challenge test

Bakr, A. **; Saad, M. A.*; Barghouth, W. M.*; Ibrahim, M. M.*; Abd El Aty, M.; Aly, S. M.** and Farag, M. A.****

*Central Laboratory for Evaluation of Veterinary Biologics, Abbassia, Cairo.

** Veterinary Serum and Vaccine Research institute, Abbassia, Cairo.

Received: 15/03/2011

Accepted: 20/03/2011

SUMMARY

Foot-and-mouth disease virus (FMDV) serotypes (O/1/3/93) and (A /Egy/2009), grown on BHK-21 clone 13 monolayer cell line, inactivated with Binary Ethylenimine (BEI) and adjuvanted with 30% Alhydrogel [AL(OH)₃] were used for preparation of bivalent gel adjuvant vaccine currently used in Egypt. 146s was measured using sucrose density gradient ultracentrifugation and vaccine dose was estimated as 4.2 µg of 146s viral proteins for each vaccine serotypes. Evaluation and testing of FMD vaccine for safety, sterility and potency were carried out. Cattle protective dose 50% (PD₅₀) was determined. The specific developed neutralizing antibody responses against different doses of bivalent vaccine in correlation with the challenge exposure test for serotype (O1/3/93) virus that was done 21 days post vaccination were undertaken. The

obtained potency of a vaccine with an overall 50% cattle protective dose (PD₅₀) value was 9.99 (PD₅₀) for serotype (O/ 1/3/93).

INTRODUCTION

Foot-and-mouth disease (FMD) is an extremely contagious viral disease of cloven-hoofed domesticated as well as wild animals and has a great potential for causing severe economic loss. The causal agent, FMD virus (FMDV), is a member of the genus Aphthovirus in the family Picornaviridae and occurs as seven distinct serotypes throughout the world: A, O, C, Asia1 and South African Territories (SAT) 1-3. Vaccination is the most important control and eradication strategy for FMD (Balamurugan et al., 2004, Mason et al., 2003 and Li et al., 2010). In many countries with endemic or with frequent introductions of FMD virus, the control of the disease mainly relies on vaccination of cattle and

other susceptible species. As the economic impact of an FMD outbreak can be large, the quality control of vaccines in most countries is strictly regulated, and in Europe, animal challenge tests are prescribed to show vaccine efficacy. As a result of such a challenge test, animals are either considered protected against clinical signs or not (Goris et al., 2007 and Syed et al., 2008).

In Egypt, where the disease is endemic, prophylactic vaccination is the only means of control. Aluminum hydroxide gel vaccine has been used to control the disease. The Recommendations of the 14th Conference of the Permanent Commission of the Office International des Epizooties (OIE) on Foot and Mouth Disease 1975 and (Pay and Hingley 1992a) form the basis for the testing of foot and mouth disease (FMD) vaccine potency. They require that potency should be measured by a quantitative method, and the minimum acceptance level for any assay method should be lower 95% confidence limit equates with a level of 70% protection in cattle after primary vaccination with a single dose following the observation by Wild and Brown (1968).

It is now well recognized that the major immunogenic component in preparations of foot-and-mouth disease (FMD) virus is the intact virion, the 146s antigen. However, preparations of some FMD strains can contain, in addition to intact virions, quantities of empty particles, the 75S antigen,

which is also immunogenic (Pay 1971, Rweyemamu et al., 1979; and 1984, Doel and Chong 1982 and Pay and Hingley 1987). The 12S subunit antigen is of extremely low immunogenicity and plays no real part in the immunogenicity of conventional FMD vaccines. This study designed and aimed to get safe, efficient and good quality FMD bivalent vaccine by application of restricted evaluation potency.

MATERIALS AND METHODS

1- Cell culture:

Baby hamster kidney (BHK-21) clone 13 monolayer cell line was kindly supplied by the Department of FMD, Veterinary Serum and Vaccine Research Institute (VSVRI), Abbassia, Cairo and used for the vaccine preparation and in Serum Neutralization Test (SNT). (Macpherson and Stocher, 1962 and Mowat, 1974)

2-Virus:

Foot-and-Mouth Disease vaccinal strains serotypes (O/ 1/ 3/ 93) and (A/ Egy/ 2009) are maintained at FMD department, (VSVRI), were used for the vaccine production. Each strain (O, A) was passaged once in cattle tongue epithelium and then adapted to BHK-21 clone 13 monolayer cell line. The two virus strains at the 6th passage level were used as seed virus which reseeded to BHK-21 clone 13 monolayer cell line and the cell associated and cell free virus content

from both inoculated monolayer were collected 16–18 hrs post inoculation and kept frozen.

3- Vaccine preparation:

The cell culture supernatant of FMD virus of the 7th passage on BHK monolayer with titer of 10^8 TCID₅₀ of both serotypes (O1/3/93/Egypt and A/Egy/2009) were concentrated to 1/10 of the original volume using Polyethylene glycol (PEG) 6000 according to Pay and Hingley (1987). The harvested concentrated viruses were treated with chloroform in concentration of 1.5% (Volume/Volume) at (4 - 8°C) for one hour , then clarified by centrifugation at 6000 g for 30min. at (4-8 °C) and stored for further using. Both virus serotypes were inactivated with 1% of 0.1M of Binary ethylenimine

(BEI) in 0.2N NaOH and the pH adjusted to 8.0 by sodium bicarbonate. The virus and BEI mixture was mixed well and incubated at 37°C for 24 hours with continuously stirring for inactivation of both virus serotypes. Sodium thiosulphate was added to give a final concentration of 2% to neutralize the action of (BEI).The inactivated FMDV suspension (35% for “O” type and 35% for “A” type), was adjuvanted with 30% aluminum hydroxide gel and stirred on a magnetic stirrer for 2 hrs. to obtained homogenized solution and Saponine was added in concentration 1.5µg/dose as immunostimulant. FMDV concentration in the final vaccine formula was adjusted to

equal to 4.2 µg of 146s for each type of the virus per vaccine dose , PH brought to 8.2 with glycol buffer and Sodium thiomersal was used as preservative at a final concentration of 0.0001 (1ml of 10% Sod Thiomersal /10 liter vaccine) according to Moussa et al., (1976). Vaccine of the both serotypes was prepared and equal quantities of each mixed to make a bivalent vaccine. The vaccine was stored at (4-8 °C) until use.

4-Estimation of 146s to determine cattle dose:

The 146S antigen of each viral fluids was estimated before and after virus concentration by using sucrose density gradient ultracentrifugation by determination the absorbance at 254 nm using (ISCO 520 C Density Gradient system) as described by (Doel and Chong, 1982 and Barteling et al., 1990). The concentration of payload antigen of inactivated viral antigen was maintained at 4.2 µg 146S viral particles/dose/serotype.

(The OIE Code sated that the dose should contain not less than 2 µg/dose/serotype.)

5-Animals:

Three groups of clinically, apparently healthy and FMDV free cattle aged 12–18 months (5calves/each). They were vaccinated with recommended dose (2ml), (0.6ml) and (0.2ml); respectively of bivalent vaccine (antigen payload 4.2 µg 146S viral particles/dose) subcutaneously in the dewlap. Another two unvaccinated healthy FMDV

antibody free cattle aged 12–18 months were kept as unvaccinated controls.

6-Sterility test:

Vaccine was tested for its sterility and purity from any bacterial or fungal contaminants. Vaccines samples were cultured on thioglycolate broth, Sabouraud's, Nutrient agar and phenol dextrose media. If any viable microorganisms were detected, the vaccine was considered unsuitable for field use, according to Code of Federal Regulation of USA (1986)

7 -Safety Test:

Three susceptible cattle were inoculated by single dose of recommended vaccinal dose (2ml) intradermo - lingual in at least (20) sites of the tongue, 4 days later (3x) dose of recommended vaccinal dose was inoculated subcutaneously. After 7 days the vaccine considered safe as no local or general lesions appear and no rise of temperature (Henderson, 1970).

8- Challenge Test:

Three weeks post vaccination the three groups were inoculated by (10^4) cattle infective dose 50 (ID₅₀) of the homologous virus serotype (O1/3/93) by intradermo-lingual route and also the two unvaccinated control ones. Animals were observed for 7 days post inoculation of challenge virus. The cattle protective dose 50% (PD₅₀) is calculated by the method of Reed and Muench, (1938).

9-Serological tests:

Blood samples for sera were collected pre and weekly post vaccination and post challenge from all animals and Serum neutralization test (SNT) was performed by the micro technique as described by (Ferreira, 1976 and Pay and Hingley, 1992b). The SN titer of the serum was expressed as the log₁₀ of the inverse dilution which protected 50% of wells and (PD₅₀) were calculated (Reed and Muench, 1938).

RESULTS AND DISCUSSION

The potency of FMD vaccine regularly expressed as the number of 50% of cattle protective dose (PD₅₀) contained in the dose of the vaccine (Berlinzani et al.,1998).Table (1) illustrated SNT titers of cattle vaccinated with different doses of bivalent FMD vaccine (2ml, 0.6ml and 0.2ml) where the mean SNT antibody titers of cattle in the 1st. week for both serotypes and different doses of vaccine were (0.84-0.81, 0.66-0.66 and 0.6-0.6) for serotypes (O&A) respectively while at end of the 2nd week the mean titers were elevated to reach (1.44-1.38 , 1.11-1.14 and 0.9-0.9). At 21 days post vaccination by the third week the mean titers were still elevated (1.89-1.83, 1.56-1.56 and 1.23-1.26) and challenge FMD virus serotype (O/1/3/93) was inoculated so the means titers for (O) strain were dropped at 4th week to (1.68, 1.38 and 1.14) while the means titers for (A) strain

showed persistent elevation to (1.89 , 1.56 and 1.41).

Table (2) showed the changes in body temperature of all animals in the different groups through 8 days post challenge with FMD virus serotype (O/1/3/93) included two positive control ones, as animals number (2 , 3 and 5) of group one , number (6 , 8 and 9) of group two and number (12 , 13 and 15) of group three showed slightly elevation of temperature from the 1st day post challenge and lasted for 3 days ,while animals number (10) of group two and number (11 and 14) of group three showed high elevation of temperature and also the two control animals. These changes in body temperature of post challenge test were correlated with protection, severity of infection and sight of lesions in relation to different doses of vaccine that represented in Table (3). The animals number (13 and 15) of group three showed local lesion on the tongue while animals number (10) of group two and numbers (11 and 14) of group three and two control animals showed severe generalized lesions in mouth, fore and hind limbs. The cattle protective dose 50% (PD₅₀) was calculated

in Table (3) as 9.99 (PD₅₀) and the results were confirmed by the 146S antigen estimation which showed also in Table (3) as (4.2 µg / virus / dose) all these results and observations are supported by (Pay and Hingley 1992b) who stated that the relationships between serum neutralizing antibody response log₁₀ of the inverse dilution and protection from challenge following a single dose primary vaccination and also by Li et al., (2010) who recorded that the antibody titer is one of referenced criteria to evaluate vaccine potency as it is positively linked with protection rate , but it influenced by factors such as vaccine' s antigen content (146S) , animal individual status. Also, other studies of Rweyemamu et al., (1979), Doel and Chong (1982) , Pay and Hingley (1987) , Pay (1971) and Rweyemamu et al., (1984) stated that the major immunogenic component in preparation of FMD virus is the intact Virion , the (146S) antigen in addition to (75S) antigen in some FMD virus strains . From this study, we proposed the estimation of (146S) antigen content of FMD virus as a great efficient method for support vaccine production.

Table: (1): FMDV Potency Evaluation by SNT (up to 28 day post vaccination)

| Animal No. | Intervals | Pre-vaccination screen | | Day 0 | | Day 7 | | Day 14 | | Day 21 * | | Day 28 | | |
|------------|-------------------------|------------------------|---|---------|---------|---------|---------|---------|---------|----------|---------|---------|---------|--|
| | Serotype | O titer | A titer | O titer | A titer | O titer | A titer | O titer | A titer | O titer | A titer | O titer | A titer | |
| 1 | Vaccine dose 2.00 ml | 0.00 | 0.3 | 0.00 | 0.3 | 0.9 | 0.6 | 1.5 | 1.2 | 1.8 | 1.65 | 1.5 | 1.8 | |
| 2 | | 0.00 | 0.00 | 0.00 | 0.00 | 0.6 | 0.75 | 1.2 | 1.5 | 1.5 | 1.8 | 1.5 | 1.95 | |
| 3 | | 0.6 | 0.3 | 0.6 | 0.3 | 0.9 | 0.9 | 1.35 | 1.35 | 1.8 | 1.95 | 1.8 | 2.1 | |
| 4 | | 0.3 | 0.45 | 0.3 | 0.45 | 1.2 | 0.9 | 1.8 | 1.65 | 2.4 | 2.1 | 1.95 | 1.8 | |
| 5 | | 0.00 | 0.00 | 0.00 | 0.00 | 0.6 | 0.75 | 1.35 | 1.2 | 1.95 | 1.65 | 1.65 | 1.8 | |
| | | | | | | | | | | | | | 1.68 | |
| 6 | Vaccine dose 0.6 ml | 0.00 | 0.00 | 0.00 | 0.00 | 0.75 | 0.75 | 1.2 | 1.2 | 1.8 | 1.65 | 1.5 | 1.8 | |
| 7 | | 0.6 | 0.6 | 0.6 | 0.6 | 0.9 | 0.9 | 1.5 | 1.35 | 1.95 | 1.8 | 1.65 | 1.65 | |
| 8 | | 0.6 | 0.9 | 0.6 | 0.9 | 0.9 | 0.9 | 1.2 | 1.2 | 1.5 | 1.65 | 1.5 | 1.8 | |
| 9 | | 0.00 | 0.00 | 0.00 | 0.00 | 0.3 | 0.3 | 0.75 | 1.05 | 1.35 | 1.5 | 1.2 | 1.35 | |
| 10 | | 0.3 | 0.00 | 0.3 | 0.00 | 0.45 | 0.45 | 0.9 | 0.9 | 1.2 | 1.2 | 1.05 | 1.2 | |
| | | | | | | | | | | | | | 1.38 | |
| 11 | Vaccine dose 0.2 ml | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.9 | 0.9 | 1.35 | 1.2 | 1.2 | 1.35 | |
| 12 | | 0.9 | 0.9 | 0.9 | 0.9 | 1.05 | 0.75 | 1.2 | 1.2 | 1.35 | 1.5 | 1.35 | 1.65 | |
| 13 | | 0.6 | 0.6 | 0.6 | 0.6 | 0.75 | 1.05 | 1.05 | 1.2 | 1.5 | 1.5 | 1.2 | 1.5 | |
| 14 | | 0.00 | 0.00 | 0.00 | 0.00 | 0.3 | 0.3 | 0.6 | 0.6 | 0.9 | 1.2 | 1.05 | 1.35 | |
| 15 | | 0.00 | 0.00 | 0.00 | 0.00 | 0.3 | 0.3 | 0.75 | 0.6 | 1.05 | 0.9 | 0.9 | 1.2 | |
| | | | | | | | | | | | | | 1.14 | |
| 16 | Control | 0.00 | *(Day 21 PV) application of Challenge Test by serotype (O1/3/93). | | | | | | | | | | | |
| 17 | | 0.00 | | | | | | | | | | | | |

• Protective antibody titer (log10) = 1.2.

Table (2): FMD Potency Evaluation Through Temperature (°C) (Post Challenge)

| Animal No. | Intervals | Day 0 | Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | Day 8 |
|-------------------|---------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|
| | Temp | (°C) | (°C) | (°C) | (°C) | (°C) | (°C) | (°C) | (°C) | (°C) |
| 1 | Vaccine dose 2.00 ml | 38.6 | 38.3 | 38.5 | 38.5 | 38.2 | 38.3 | 38.3 | 38.2 | 38.2 |
| 2 | | 39.5 | 38.0 | 38.5 | 38.8 | 37.9 | 37.9 | 37.8 | 37.7 | 37.6 |
| 3 | | 38.9 | 40.0 | 38.2 | 38.6 | 38.2 | 38.0 | 38.1 | 38.1 | 38.0 |
| 4 | | 39.0 | 38.9 | 38.8 | 39.0 | 38.4 | 38.6 | 38.5 | 38.4 | 38.4 |
| 5 | | 38.8 | 38.5 | 38.6 | 39.7 | 38.5 | 38.2 | 38.3 | 38.3 | 38.2 |
| 6 | Vaccine dose 0.6 ml | 38.7 | 40.1 | 38.6 | 38.9 | 38.2 | 38.2 | 38.2 | 38.1 | 38.0 |
| 7 | | 39.3 | 38.9 | 38.9 | 38.8 | 38.6 | 38.7 | 38.6 | 38.5 | 38.4 |
| 8 | | 38.8 | 39.1 | 39.1 | 40.2 | 38.8 | 38.3 | 38.3 | 38.3 | 38.5 |
| 9 | | 38.8 | 40.9 | 39.9 | 39.6 | 38.6 | 38.2 | 38.3 | 38.2 | 38.4 |
| 10 | | 39.0 | 39.5 | 40.8 | 40.0 | 39.6 | 39.1 | 39.1 | 39.0 | 39.1 |
| 11 | Vaccine dose 0.2 ml | 38.6 | 40.2 | 40.4 | 40.0 | 38.3 | 39.3 | 38.8 | 38.7 | 38.7 |
| 12 | | 38.7 | 39.3 | 38.8 | 39.1 | 38.7 | 40.1 | 39.2 | 39.3 | 39.2 |
| 13 | | 38.5 | 40.3 | 39.7 | 39.2 | 38.0 | 38.5 | 38.3 | 38.4 | 38.4 |
| 14 | | 38.8 | 39.8 | 40.5 | 40.2 | 38.4 | 38.7 | 38.6 | 38.5 | 38.4 |
| 15 | | 38.9 | 40.1 | 38.8 | 39.0 | 38.3 | 38.5 | 38.5 | 38.5 | 38.3 |
| 16 | control | 38.7 | 40.9 | 40.1 | 39.8 | 38.9 | 38.6 | 38.6 | 38.6 | 38.5 |
| 17 | | 38.9 | 39.2 | 40.9 | 39.9 | 39.0 | 38.8 | 38.8 | 38.7 | 38.7 |

- Normal temperature of Cattle (38.0 – 38.4 °C)

Table (3): Inspection of FMD lesions (Post Challenge)

| Animal No. | Vaccine dose | Left Front Leg | | Right Front Leg | | | | Left Hind Leg | | | | Right Hind Leg | | | | Tongue | Palatum | Gum | Dental Pad | Nose | | |
|------------|--------------|----------------|-----|-----------------|-----|------|-----|---------------|-----|------|-----|----------------|-----|------|-----|--------|---------|-----|------------|------|--------|-----|
| | | Claw | | Byclaw | | Claw | | Byclaw | | Claw | | Byclaw | | Claw | | | | | | | Byclaw | |
| | | Lat | Med | Lat | Med | Lat | Med | Lat | Med | Lat | Med | Lat | Med | Lat | Med | | | | | | Lat | Med |
| 1 | 2 ml | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | | |
| 2 | | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | | |
| 3 | | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | | |
| 4 | | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | | |
| 5 | | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | | |
| 6 | | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | | |
| 7 | 0.6 ml | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | | |
| 8 | | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | | |
| 9 | | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | | |
| 10 | | + | + | - | - | + | + | - | - | + | + | - | - | + | + | - | - | + | - | | | |
| 11 | 0.2 ml | + | + | - | - | + | + | - | - | + | + | - | - | + | + | - | - | + | - | | | |
| 12 | | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | | |
| 13 | | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | | |
| 14 | | + | + | - | - | + | + | - | - | + | + | - | - | + | + | - | - | + | - | | | |
| 15 | | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | | |
| 16 | control | + | + | - | - | + | + | - | - | + | + | - | - | + | + | - | - | + | + | | | |
| 17 | | + | + | - | - | + | + | - | - | + | + | - | - | + | + | - | - | + | - | | | |

CACULATED (PD50) 9.99

The concentration of antigen of inactivated viral antigen was maintained at 4.2 µg 146S viral particles/dose/serotype.

REFERENCES

- Balamurugan V, Kumar RM and Suryanarayana VV (2004): Past and present vaccine development strategies for the control of foot and mouth disease. *Acta Virol*, 48(4):201-14.
- Barteling, S. J., van Maanen, C., Yadin, H. and Anemaet, D. A. J. (1990): A foot-and-mouth disease vaccine bank: purified inactivated antigen stored at ultra-low temperatures for the rapid preparation of double oil emulsion (D.O.E.) vaccines. European Commission for the Control of Foot-and-Mouth Disease. Session of the Research Group of the Standing Technical Committee, Lindholm, 1990, pp. 172-177
- Berlinzani, A.; Brocchi, E. and DeSimone, F. (1998): Performance of the 3ABC-trapping ELISA to differentiate infected from vaccinated animals in a field situation. Experience following FMD outbreaks in Albania. European Commission for the Control of FMD disease: 166-171.
- Brown, F. (1985). Vaccination against foot-and-mouth disease: past, present and future. *Annals Institut Pasteur* 136E, 547-552.
- Code of Federal regulation of USA (1986): Animal and animal products 9\1986. Published by the office of the federal register national archives and Record administration
- Doel, T. R. and Chong, W. K. T. (1982): Comparative immunogenicity of 146S, 75S and 12S particles of foot-and-mouth disease virus. *Arch. Virol.*, 73, 185
- Ferreira M. E. V. (1976): Prubade microneutralization poraestudies de anticueropos de la fibre ftosa. 3th Centropanamericano Fiebre Aftosa, (21/22): 17-24.
- Goris N, MerkelbachPeters P, Diev VI, Verloo D, Zakharov VM, Kraft HP(2007): European Pharmacopoeia footandmouth disease vaccine potency testing in cattle: between test variability and its consequences. *Vaccine*; 25(17):373– 379.
- Henderson W. M. (1970): Foot and mouth disease; a definition of the problem and view on its solution. *Br. Vet. J.*, 126: 115-120.
- Li et al. Dong Li*, Zeng-Jun Lu, Bao-Xia Xie, Pu Sun, Ying-Li Chen, Yuan-Fang Fu, Zai-Xin Liu (2010): Alternative way to test the efficacy of swine FMD vaccines: measurement of pigs median infected dose (PID50) and regulation of live virus challenge dose *Virology Journal*, 7:215 – 217
- Lewis, A. E. (1991): Significance of animal products in the spread of Foot and Mouth disease. *Full. Off. Int. Epiz.*, 87(9/10): 855-858
- Mastan, M. B.; Amighi, M.; Ardelan, A.; Bandpay, M. R.; Ebadi, A. and Farsi, J. (1976): "Preliminary study of the combination of anti-FMD and anti-brucellosis vaccines". *Dev. Biol. Stand.*, 35: 437-443.
- Mason PW, Chinsangaram J, Moraes MP, Mayr GA, Grubman MJ (2003): Engineering better vaccines for foot-and-mouth disease. *Dev Biol*, 114:79-88
- Macpherson and Stocher (1962): "Polyma transformation hamster cell clones, an investigation of gebetic factors affecting cell competence". *Virology*, 16: 147-151.
- Moussa, A. A. M., Daoud, A., Hussein, K., Hassan, N. A., Fahmy, F., Azab, A. and El-Shehawy, L. (1984): Prevalence of FMD in Egypt. *Agric. Res. Rev.*: 62 (5B), 55-63.
- Mowat, G. N. (1974): Potency of BHK-produced foot-and-mouth disease vaccines after storage. *Bull. Off. Int. Epizoot*, 82, 115t
- Office International des Epizooties. Recommendations of 14thConference of the Commission on Foot and Mouth Disease. *Bull. Off. Int. Epizoot*. 1975, 83, 557-559
- OIE (Office International des Epizooties) (2000): Foot and mouth disease, Chapter 2.1.1. In manual of standards for diagnostic tests and vaccine, 4th Ed. 2000, Paris, 77-92.

- OIE (2006): Disease information 16 February 2006; 19 (7): 16-19.
- Pay, T. W. F. (1971): The effect of the antigen dose on the immune responses following primary and secondary FMD vaccination of cattle. *Prec. 2nd Int. Congr. Virol. Budapest, Int. Virol* 1971, 2, 154
- Pay T. W. F., Hingley P. J. (1987): Correlation of 140S antigen dose with the serum neutralizing antibody response and the level of protection induced in cattle by foot and mouth disease vaccines. *Vaccine*; 5(1):60-64.
- Pay T. W. F. and Hingley P. J. (1992a) Foot and mouth disease vaccine potency tests in cattle: the interrelationship of antigen dose, serum neutralizing antibody response and protection from challenge. *Vaccine*; 10(10):699-706.
- Pay, T. W. F. and Hingley, P. J. (1992 b): A potency test method for foot and mouth disease vaccine based on the serum neutralizing antibody response produced in cattle. *Vaccine*, 10, 707-713
- Reed, L. J. and Muench, H. (1938): A simple method for estimating fifty percent (50%) end points. *Amer. J. Hyg.*, 27: 493-497.
- Rweyemamu, M. M., Terry, G. and Pay, T. W. F. (1979): Stability and immunogenicity of empty particles of foot-and-mouth disease virus. *Arch. Virol.*, 59, 69
- Rweyemamu, M. M., Black, L., Boge, A., Thorne, A. C. and Terry, G. M. (1984): The relationship between 140S antigen dose in aqueous foot and mouth disease vaccines and the serum antibody response of cattle. *J. BioL Stand.*, 12, 111- 120
- Syed M. Jamala, b, Annemarie Boumaa, Jan van den Broeka, Arjan Stegema, Gilles Chénard, Aldo Dekker, (2008): Foot and mouth disease vaccine potency testing: The influence of serotype, type of adjuvant, valency, fractionation method, and virus culture on the dose response curve in cattle *Vaccine* 26 ,6317-6321
- Wild, T. F. and Brown, F. A (1968): study of the physical properties of the immunising antigen of foot-and-mouth disease virus and the effect of various inactivating agents on its structure. *Arch. Ges. Virusforsch.* , 24, 86

تحضير لقاح الحمى القلاعية ثنائى العترة (O & A) بحساب كمية 146s لجرعة

الأبقار و تقييمه باستخدام الطرق السيرولوجية و اختبار التحدى.

*أحمد بكر، **محمد أحمد سعد، **وليد محمد عبد الرحمن برغوث، **ماجد منير إبراهيم،

*مجدى عبد العاطى، *سمير محمد على، *مختار عامر

*معهد بحوث الأمصال واللقاحات البيطرية-العباسية- القاهرة

**المعمل المركزى للرقابة على المستحضرات الحيوية البيطرية

تم خلال هذا العمل تمرير و تنمية عترتى فيروس الحمى القلاعية النوع (A/Egypt/2009) و (O/1/3/93) على المزارع النسيجية لخلايا كلى اليربوع الذهبى السورى (BHK-21cl 13) و أبطال تأثيريهما باستخدام مادة البنارى أثيل أمين (BEI) و اضافة مادة الهيدراجيل المحفزة بتركيز 30% و ذلك لتحضير اللقاح ثنائى العترة وسيلة الوقاية الرئيسية المستخدم حاليا فى مصر. تم قياس الأنتجين (146s) باستخدام الطرد المركزى الفائق خلال السكروس متدرج الكثافة و من خلال ذلك قدر محتوى جرعة اللقاح بقيمة 4.2 ميكروجرام من البرتين الفيروسى (146s) لكل عترة من اللقاح. تم تقييم و اجراء اختبارات السلامة و النقاوة و الفاعلية لللقاح بالاضافة لتقدير جرعة حماية الأبقار (PD₅₀). وقد أكدت الدراسة أن تقدير استجابة الأجسام المناعية المتخصصة للجرعات المختلفة من اللقاح و اجراء اختبار التحدى باستخدام عترة الفيروس (O/1/3/93) فى اليوم 21 بعد اجراء التحصين جاءت متوافقة مع مستوى الحماية و من خلال ذلك تم حساب قوة اللقاح الذى يوفر الحماية لنسبة 90% من الأبقار (PD₅₀) و التى كانت بقيمة 9.99 للنوع (O/1/3/93) من عترة الفيروس.